Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

29. April 2021

April 2021,
by Stephen Hansen

Download

Search for:

Adrenomed to attend upcoming industry and investor conferences

13. October 2022

Adrenomed appoints David Germonpré as Chief Financial Officer

12. July 2022

Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

23. June 2022

PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

11. April 2022

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

15. March 2022

Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

2. December 2021

More News

Media Coverage

Article in GoingPublic’s Plattform Life Sciences: “A phenomenal breakthrough is taking shape”

4. July 2022

Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial

12. April 2022

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

19. October 2021

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

28. July 2021

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

19. May 2021

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

29. April 2021

Recent Events

March conference update: 41st ISICEM and BIO-Europe Spring 2022

7. March 2022

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

26. November 2021

Weimar Sepsis Update, September 8 – 10, 2021

23. August 2021

ISICEM, August 31 – September 3, 2021

23. August 2021

BIO Digital, 10–18 June, 2021

7. June 2021

Bio€quity Europe, 17–19 May, 2021

19. April 2021

More Events

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

Recent News

Adrenomed to attend upcoming industry and investor conferences

Adrenomed appoints David Germonpré as Chief Financial Officer

Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock

Media Coverage

Article in GoingPublic’s Plattform Life Sciences: “A phenomenal breakthrough is taking shape”

Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

Interview with Deutsche Welle: Is it becoming easier to get financing for innovation?

Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial

Recent Events

March conference update: 41st ISICEM and BIO-Europe Spring 2022

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

Weimar Sepsis Update, September 8 – 10, 2021

ISICEM, August 31 – September 3, 2021

BIO Digital, 10–18 June, 2021

Bio€quity Europe, 17–19 May, 2021

Archive